Lymphoma-CLL/SLL

Primary Site	Histology	Behavior
C000-C440, C442-C689, C691-C694, C698-C699, C739-C750, C754-C809	9823	<Any value>
C700-C729, C751-C753	9823	3

Notes

9823 (EXCEPT C441, C690, C695-C696) **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schema for the listed primary sites * C441, C690, C695-C696 (9823): *Lymphoma Ocular Adnexa* **Note 3:** Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL/SLL) is always staged as a lymphoma. **Note 4:** The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE. **Note 5:** In addition to coding EOD Primary Tumor, the following data items are also needed to assign a stage group for CLL/SLL. * Lymphocytosis * Adenopathy * Organomegaly * Anemia * Thrombocytopenia

Data Items
Staging Methods
Outputs

Data Items

Name	Default Value	Used in Derivation	NAACCR Item	Required By	Metadata
Year of Diagnosis		No	NAACCR #390 dateOfDiagnosis		None
Primary Site		Yes	NAACCR #400 primarySite		None
Histology		Yes	NAACCR #522 histologicTypeIcdO3		None
Behavior		Yes	NAACCR #523 behaviorCodeIcdO3		None
Tumor Size Clinical	999	No	NAACCR #752 tumorSizeClinical		None
Tumor Size Pathological	999	No	NAACCR #754 tumorSizePathologic		None
Tumor Size Summary	999	No	NAACCR #756 tumorSizeSummary		None
Regional Nodes Positive	99	No	NAACCR #820 regionalNodesPositive		None
Regional Nodes Examined	99	No	NAACCR #830 regionalNodesExamined		None
EOD Primary Tumor	999	Yes	NAACCR #772 eodPrimaryTumor		None
EOD Regional Nodes	888	Yes	NAACCR #774 eodRegionalNodes		None
EOD Mets	88	Yes	NAACCR #776 eodMets		None
SS2018		No	NAACCR #764 summaryStage2018		None
Grade Clinical	8	Yes	NAACCR #3843 gradeClinical	All	SSDI
Grade Pathological	8	Yes	NAACCR #3844 gradePathological	All	SSDI
Grade Post Therapy Clin (yc)		No	NAACCR #1068 gradePostTherapyClin	COC NPCR SEER	SSDI
Grade Post Therapy Path (yp)		No	NAACCR #3845 gradePostTherapy	CCCR/Canada COC NPCR SEER	SSDI
B Symptoms	8	No	NAACCR #3812 bSymptoms	CCCR/Canada COC SEER	SSDI
HIV Status	8	No	NAACCR #3859 hivStatus	COC 2018–2020 SEER	SSDI
NCCN International Prognostic Index (IPI)	X8	No	NAACCR #3896 nccnInternationalPrognosticIndex	COC SEER	SSDI
Lymphocytosis		Yes	NAACCR #3885 lymphocytosis	All	SSDI
Adenopathy		Yes	NAACCR #3804 adenopathy	All	SSDI
Organomegaly		Yes	NAACCR #3907 organomegaly	All	SSDI
Anemia		Yes	NAACCR #3811 anemia	All	SSDI
Thrombocytopenia		Yes	NAACCR #3933 thrombocytopenia	All	SSDI

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Start

Additional Context

eod_2018_stage_group = 90

Next Step

EOD Mets
EOD Mets
ss2018_m